Drylock and Ontex, two of Europe's largest private-label hygiene products manufacturers, are engaged in a patent dispute in Germany, according to a report by Nonwovens Industry. Details of the case — including the specific patents at issue, the filing court, and the relief sought — remain unconfirmed, and neither company has issued a public statement on the matter at the time of writing.

The report, surfaced via trade press monitoring, names Germany as the jurisdiction. That jurisdictional detail matters for sourcing and procurement teams tracking the hygiene supply chain. Germany is a designated venue for unified patent enforcement in Europe, and German courts have historically moved quickly on injunctions in fast-moving consumer goods component disputes. For tier-one suppliers of absorbent hygiene products — diapers, adult incontinence products, and femcare — a German patent action can disrupt shipment schedules even before a final ruling.

Both companies occupy significant positions in the nonwovens value chain. Drylock, headquartered in Belgium, operates converting plants across Europe, the Americas, and Asia, and supplies private-label diapers and femcare lines to major European retailers. Ontex, listed on Euronext Brussels, runs a manufacturing footprint spanning Europe, the Americas, and Turkey, and has been restructuring its portfolio toward branded and private-label hygiene in recent years. The two compete directly for private-label volume with European grocery and drugstore chains, which makes any intellectual property clash between them a commercial question for buyers as well as lawyers.

What the dispute reportedly concerns — and what remains unverified — is the core question procurement teams should press suppliers on now. Nonwovens Industry flagged the dispute but the underlying patent claims, whether they cover manufacturing processes, product construction, or materials technology, have not been detailed in public reporting. Patent conflicts in this sector typically centre on absorbent core construction, acquisition distribution layers, elastic side panel designs, or converting line innovations. Until filings surface or the parties confirm the scope, treat the dispute as a reported matter rather than an established litigation record.

The commercial exposure cuts along familiar lines. If an injunction issues in Germany, one supplier's delivery of affected product lines into the German market could halt while workarounds are engineered. Retailers running private-label hygiene programs on tight replenishment cycles have limited tolerance for that kind of interruption. Alternative capacity exists — Drylock and Ontex between them supply a large share of European private-label volume, but rivals including Paul Hartmann, Essity's private-label arm, and several Turkish and Central European converters can absorb overflow at a price and on a lead-time penalty.

For sourcing executives, the practical checklist is short. First, identify whether any contracted hygiene SKUs sourced from either Drylock or Ontex flow through German distribution or are manufactured at German-converting sites. Second, request written confirmation from the supplier of whether the disputed patents touch contracted product specifications. Third, review force majeure, IP indemnification, and supply-continuity clauses in existing agreements — many private-label contracts drafted in standard form leave IP dispute risk with the manufacturer, but delivery failure risk sits with the retailer's shelf.

For compliance and legal teams, the dispute is a reminder that IP diligence belongs in supplier qualification, not just in new-product development. European hygiene nonwovens have seen repeated patent enforcement over the past decade, covering everything from cuff designs to sustainable material formulations. A dispute between two suppliers of this scale signals that freedom-to-operate analysis on private-label specifications may need refreshing.

Ontex investors should note the timing separately. The company has been executing a strategic overhaul, divesting emerging-market operations and concentrating on its European and North American core. Litigation costs and any production disruption in Germany would land on that programme. Drylock, privately held, discloses less, but its capacity commitments to major retail accounts mean the same operational risk applies.

The decision the news forces: procurement leads running European private-label hygiene programs should now map their exposure to both suppliers and secure contractual clarity on IP-dispute liability and alternative supply before any German court ruling narrows their options.